Development of a highly stable and targetable nanoliposomal formulation of topotecan

Journal of Controlled Release

Volumn 141, Issue 1, 2010, Pages 13-21

  Drummond, Daryl C ^a   Noble, Charles O ^a   Guo, Zexiong ^b   Hayes, Mark E ^a   Connolly Ingram, Ceirin ^a   Gabriel, Bianca S ^a   Hann, Byron ^c   Liu, Bin ^c   Park, John W ^c   Hong, Keelung ^a   Benz, Christopher C ^c,d   Marks, James D ^c   Kirpotin, Dmitri B ^a  

^a Hermes Biosciences Inc   (United States)

^b JINAN UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

Antibody targeting; ErbB2; Liposomes; Nanoparticles; Topotecan

Indexed keywords

ANTI-EGFR; ANTI-TUMOR ACTIVITIES; BREAST CANCER CELLS; CAMPTOTHECINS; CANCER CELL LINES; CELL SURFACE RECEPTORS; CELLULAR UPTAKE; COMPLEXING AGENTS; DRUG LOAD; DRUG RELEASE; ERBB2; HUMAN BREAST CANCER; IN-VIVO; INTRACELLULAR DELIVERY; LACTONE HYDROLYSIS; LACTONE RINGS; MECHANISM OF ACTION; NANOCARRIERS; NANOLIPOSOMES; NON-TARGETED; PHARMACOKINETIC PROFILES; POLYPHOSPHATES; SITE-SPECIFIC; SOLID TUMORS; TOPOTECAN; TRANSMEMBRANES;

ANTIBODIES; CELL CULTURE; CELL MEMBRANES; ENZYME INHIBITION; HYDROLYSIS; NANOPARTICLES; PHENOLS; PHOSPHOLIPIDS;

LIPOSOMES;

CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEXAMETAPHOSPHATE SODIUM; IRINOTECAN; LIPOSOME; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG RETENTION; DRUG STABILITY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RAT; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, NUDE; MOLECULAR STRUCTURE; NANOSTRUCTURES; NEOPLASMS, EXPERIMENTAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TIME FACTORS; TOPOTECAN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70849083959     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.08.006     Document Type: Article

References (50)

1. Dennis M.J., Beijnen J.H., Grochow L.B., and van Warmerdam L.J. An overview of the clinical pharmacology of topotecan. Semin. Oncol. 24 1 Suppl 5 (1997) S5-12-S15-18
2. Fassberg J., and Stella V.J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 81 7 (1992) 676-684
3. Underberg W.J., Goossen R.M., Smith B.R., and Beijnen J.H. Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. J. Pharm. Biomed. Anal. 8 8-12 (1990) 681-683
4. Burke T.G., and Gao X. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J. Pharm. Sci. 83 (1994) 967-969
5. Drummond D.C., Noble C.O., Guo Z., Hong K., Park J.W., and Kirpotin D.B. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 66 6 (2006) 3271-3277
6. Tardi P., Choice E., Masin D., Redelmeier T., Bally M., and Madden T.D. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res. 60 13 (2000) 3389-3393
7. Drummond D.C., Meyer O., Hong K.L., Kirpotin D.B., and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharm. Rev. 51 4 (1999) 691-743
8. Greish K., Fang J., Inutsuka T., Nagamitsu A., and Maeda H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin. Pharmacokinet. 42 13 (2003) 1089-1105
9. Koshkina N.V., Gilbert B.E., Waldrep J.C., Seryshev A., and Knight V. Distribution of camptothecin after delivery of a liposome aerosol or following intramuscular injection in mice. Cancer Chemother. Pharmacol. 44 (1999) 187-192
10. Knight V., Koshkina N.V., Waldrep J.C., Giovanella B.C., and Gilbert B.E. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother. Pharmacol. 44 (1999) 177-186
11. Xiang T.X., and Anderson B.D. Stable supersaturated aqueous solutions of silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin via chemical conversion in the presence of a chemically modified beta-cyclodextrin. Pharm. Res. 19 8 (2002) 1215-1222
12. Zhang J.A., Xuan T., Parmar M., Ma L., Ugwu S., Ali S., and Ahmad I. Development and characterization of a novel liposome-based formulation of SN-38. Int. J. Pharm. 270 1-2 (2004) 93-107
13. Drummond D.C., Noble C.O., Hayes M.E., Park J.W., and Kirpotin D.B. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J. Pharm. Sci. (2008)
14. Fahr A., van Hoogevest P., May S., Bergstrand N., and ML S.L. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur. J. Pharm. Sci. 26 3-4 (2005) 251-265
15. Ramsay E., Alnajim J., Anantha M., Taggar A., Thomas A., Edwards K., Karlsson G., Webb M., and Bally M. Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm. Res. 23 12 (2006) 2799-2808
16. Zamboni W.C., Strychor S., Joseph E., Walsh D.R., Zamboni B.A., Parise R.A., Tonda M.E., Yu N.Y., Engbers C., and Eiseman J.L. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clin. Cancer Res. 13 23 (2007) 7217-7223
17. Emerson D.L., Bendele R., Brown E., Chiang S., Desjardins J.P., Dihel L.C., Gill S.C., Hamilton M., LeRay J.D., Moon-McDermott L., Moynihan K., Richardson F.C., Tomkinson B., Luzzio M.J., and Baccanari D. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clin. Cancer Res. 6 7 (2000) 2903-2912
18. Messerer C.L., Ramsay E.C., Waterhouse D., Ng R., Simms E.M., Harasym N., Tardi P., Mayer L.D., and Bally M.B. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin. Cancer Res. 10 19 (2004) 6638-6649
19. Liu J.J., Hong R.L., Cheng W.F., Hong K., Chang F.H., and Tseng Y.L. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation. Anti-Cancer Drugs 13 7 (2002) 709-717
20. Ramsay E.C., Anantha M., Zastre J., Meijs M., Zonderhuis J., Strutt D., Webb M.S., Waterhouse D., and Bally M.B. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clin. Cancer Res. 14 4 (2008) 1208-1217
21. Gabizon A., Shmeeda H., and Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42 5 (2003) 419-436
22. Drummond D.C., Marx C., Guo Z., Scott G., Noble C., Wang D., Pallavicini M., Kirpotin D.B., and Benz C.C. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin. Cancer Res. 11 9 (2005) 3392-3401
23. Drummond D.C., Noble C.O., Guo Z., Hayes M.E., Park J.W., Ou C.J., Tseng Y.L., Hong K., and Kirpotin D.B. Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. J. Pharmacol. Exp. Ther. 328 1 (2009) 321-330
24. Noble C.O., Guo Z., Hayes M.E., Marks J.D., Park J.W., Benz C.C., Kirpotin D.B., and Drummond D.C. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother. Pharmacol. (2009)
25. Noble C.O., Krauze M.T., Drummond D.C., Yamashita Y., Saito R., Berger M.S., Kirpotin D.B., Bankiewicz K.S., and Park J.W. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res. 66 5 (2006) 2801-2806
26. Saito R., Krauze M.T., Noble C.O., Drummond D.C., Kirpotin D.B., Berger M.S., Park J.W., and Bankiewicz K.S. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro-oncology 8 3 (2006) 205-214
27. Wethington S.L., Wright J.D., and Herzog T.J. Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert. Rev. Anticancer Ther. 8 5 (2008) 819-831
28. Nicum S.J., and O'Brien M.E. Topotecan for the treatment of small-cell lung cancer. Expert. Rev. Anticancer Ther. 7 6 (2007) 795-801
29. M. Brave, R. Dagher, A. Farrell, S. Abraham, R. Ramchandani, J. Gobburu, B. Booth, X. Jiang, R. Sridhara, R. Justice, R. Pazdur, Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology (Williston Park) 20(11) (2006) 1401-1404, 1410; discussion 1410-1411, 1415-1406.
30. Kearney A., Patel K., and Palepu N. Preformulation studies to aid in the development of a ready-to-use injectable solution of the antiumor agent, topotecan. Int. J. Pharm. 127 (1996) 229-237
31. Nellis D.F., Ekstrom D.L., Kirpotin D.B., Zhu J., Andersson R., Broadt T.L., Ouellette T.F., Perkins S.C., Roach J.M., Drummond D.C., Hong K., Marks J.D., Park J.W., and Giardina S.L. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol. Prog. 21 1 (2005) 205-220
32. Bartlett G.R. Phosphorous assay in column chromatography. J. Biol. Chem. 234 (1959) 466-468
33. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37 (1959) 911-917
34. Nielsen U.B., Kirpotin D.B., Pickering E.M., Hong K., Park J.W., Refaat Shalaby M., Shao Y., Benz C.C., and Marks J.D. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta 1591 1-3 (2002) 109-118
35. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., and Benz C.C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8 4 (2002) 1172-1181
36. Benz C.C., Scott G.K., Sarup J.C., Johnson R.M., Tripathy D., Coronado E., Shepard H.M., and Osborne C.K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 24 2 (1992) 85-95
37. Working P.K., and Dayan A.D. Pharmacological-toxicological expert report - Caelyx(TM)-(Stealth(R) liposomal doxorubicin HCl) - foreword. Human Exp. Toxicol. 15 9 (1996) 751-785
38. Taggar A.S., Alnajim J., Anantha M., Thomas A., Webb M., Ramsay E., and Bally M.B. Copper-topotecan complexation mediates drug accumulation into liposomes. J. Control. Release 114 1 (2006) 78-88
39. Armstrong D.K., Spriggs D., Levin J., Poulin R., and Lane S. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. Oncologist 10 9 (2005) 686-694
40. Noble C.O., Kirpotin D.B., Hayes M.E., Mamot C., Hong K., Park J.W., Benz C.C., Marks J.D., and Drummond D.C. Development of ligand-targeted liposomes for cancer therapy. Expert Opin. Ther. Targets 8 4 (2004) 335-353
41. Sapra P., and Allen T.M. Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res. 42 5 (2003) 439-462
42. Gerrits C.J.H., de Jonge M.J.A., Schellens J.H.M., Stoter G., and Verweij J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br. J. Cancer 76 (1997) 952-962
43. Guichard S., Montazeri A., Chatelut E., Hennebelle I., Bugat R., and Canal P. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation. Clin. Cancer Res. 7 10 (2001) 3222-3228
44. Allen T.M., Cheng W.W., Hare J.I., and Laginha K.M. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem 6 6 (2006) 513-523
45. Abraham S.A., Edwards K., Karlsson G., Hudon N., Mayer L.D., and Bally M.B. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J. Control. Release 96 3 (2004) 449-461
46. Subramanian D., and Muller M.T. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan. Oncol. Res. 7 (1995) 461-469
47. Li X., Lu W.L., Liang G.W., Ruan G.R., Hong H.Y., Long C., Zhang Y.T., Liu Y., Wang J.C., Zhang X., and Zhang Q. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice. Eur. J. Clin. Invest. 36 6 (2006) 409-418
48. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., and Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66 13 (2006) 6732-6740
49. Mamot C., Drummond D.C., Greiser U., Hong K., Kirpotin D.B., Marks J.D., and Park J.W. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 63 (2003) 3154-3161
50. Gabr A., Kuin A., Aalders M., El-Gawly H., and Smets L.A. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Cancer Res. 57 21 (1997) 4811-4816